Klin Farmakol Farm. 2022;36(4):123-128 | DOI: 10.36290/far.2022.020

What's new in migraine therapy?

Tomáš Nežádal
Neurologické oddělení, Ústřední vojenská nemocnice, Praha
1. lékařská fakulta Univerzity Karlovy, Praha

Migraine is one of the most common and most disabling neurological diseases. Migraine treatment is aimed at reducing the intensity and duration of the headache attack itself and other bothersome symptoms, as well as at reducing the number of migraine days. Although some existing principles continue to apply, a significant shift in both acute and prophylactic therapy has been noted. The basic mechanism of the innovative treatment is the influence of calcitonin gene-related peptide (CGRP) or its receptor with monoclonal antibodies or small molecules, gepants.

Keywords: migraine, treatment, CGRP, monoclonal antibodies, gepants.

Accepted: February 8, 2023; Published: February 8, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nežádal T. What's new in migraine therapy? Klin Farmakol Farm. 2022;36(4):123-128. doi: 10.36290/far.2022.020.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z; Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137. Go to original source... Go to PubMed...
    2. Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, Lipton RB. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52(10):1456-1470. Go to original source... Go to PubMed...
    3. Nežádal T, Marková J, Bártková A, Doležil D, Mastík J, Kotas R, Niedermayerová I, Grunermelová M, Klečka L. Mezinárodní klasifikace bolestí hlavy (ICHD-3) - oficiální český překlad. Cesk Slov Neurol N 2020;83/116(2):145-152. Go to original source...
    4. Affaitati G, Fabrizio A, Lopopolo M. Use of NSAIDs for migraine attacks: Results from retrospective analysis in Italian headache center. Presented in 15th World Congress on Pain, Buenos Aires, October 6-11, 2014.
    5. Spielmann K, Kayser A, Beck E, Meister R, Schaefer C. Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study. Cephalalgia. 2018;38(6):1081-1092. Go to original source... Go to PubMed...
    6. Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB; COL MIG-301 Study Group. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018;91(24):e2222-e2232. Go to original source... Go to PubMed...
    7. Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745. Go to original source... Go to PubMed...
    8. Nežádal T, Marková J, Bártková A, Klečka L. CGRP monoklonální protilátky v léčbě migrény - indikační kritéria a terapeutická doporučení pro Českou republiku. Cesk Slov Neurol N 2020;83/116(4):445-451. Go to original source...
    9. Hepp, Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 2015;35(6):478-488. Go to original source... Go to PubMed...
    10. Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51-60. Go to original source... Go to PubMed...
    11. Lipton RB, Pozo-Rosich P, Blumenfeld A, Li Y, Severt L, Stokes JT, Creutz L, Gandhi P, Dodick D. Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial. Neurology. 2022 Nov 17:10.1212. Go to original source... Go to PubMed...
    12. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF; PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30:804-814. Go to original source... Go to PubMed...
    13. Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A. Long term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018;19(1):13. Go to original source... Go to PubMed...
    14. Kamm K, Straube A, Ruscheweyh R. Calcitonin gene-related peptide levels in tear fluid are elevated in migraine patients compared to healthy controls. Cephalalgia 2019;39(12):1535-1543. Go to original source... Go to PubMed...
    15. Edvinsson L. The CGRP Pathway in Migraine as a Viable Target for Therapies. Headache. 2018;58 Suppl 1:33-47. Go to original source... Go to PubMed...
    16. Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med 2017;377:2123-2132. Go to original source... Go to PubMed...
    17. Ferrari MD, Reuter U, Goadsby PJ, Paiva da Silva Lima G, Mondal S, Wen S, Tenenbaum N, Pandhi S, Lanteri-Minet M, Stites T. Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study. J Neurol Neurosurg Psychiatry. 2022;93(3):254-262. Go to original source... Go to PubMed...
    18. Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, Assetta M, Maddestra M, Marzoli F, Viola S, Cerone D, Marini C, Pistoia F, Sacco S. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. Headache Pain 2020;21(1):32. Go to original source... Go to PubMed...
    19. Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F, Zhang F, Paiva da Silva Lima G, Cheng S, Mikol DD. Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol. 2021;28(5):1716-1725. Go to original source... Go to PubMed...
    20. Cullum CK, Do TP, Ashina M, Bendtsen L, Hugger SS, Iljazi A, Gusatovic J, Snellman J, Lopez-Lopez C, Ashina H, Amin FM. Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study. J Headache Pain. 2022;23(1):61 Go to original source... Go to PubMed...
    21. Ornello R, Baraldi C, Guerzoni S, Lambru G, Fuccaro M, Raffaelli B, Gendolla A, Barbanti P, Aurilia C, Cevoli S, Favoni V, Vernieri F, Altamura C, Russo A, Silvestro M, Dalla Valle E, Mancioli A, Ranieri A, Alfieri G, Latysheva N, Filatova E, Talbot J, Cheng S, Holle D, Scheffler A, Nežádal T, Čtrnáctá D, Šípková J, Matoušová Z, Sette L, Casalena A, Maddestra M, Viola S, Affaitati G, Giamberardino MA, Pistoia F, Reuter U, Sacco S. Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in Men. Front Neurol. 2021;12:774341 Go to original source... Go to PubMed...
    22. Ehrlich M, Hentschke C, Sieder C, Maier-Peuschel M, Reuter U. Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study. J Headache Pain. 2022;23(1):141. Go to original source... Go to PubMed...
    23. Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA 2018;319:1999-2008. Go to original source... Go to PubMed...
    24. Silberstein SD, McAllister P, Ning X, Faulhaber N, Lang N, Yeung P, Schiemann J, Aycardi E, Cohen JM, Janka L, Yang R. Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials. Headache. 2019;59(6):880-890. Go to original source... Go to PubMed...
    25. Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, Mueller M, Ahn AH, Schwartz YC, Grozinski-Wollf M, Janka L, Ashina M. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 2019;394(10203):1030-1040. Go to original source... Go to PubMed...
    26. Shankin C, Broessner G, Gaul Ch, Kraya T, Hamann X., Haertel B, Neeb L, Straube A. Response to fremanezumab in migraine patients with and without prior aCGRP mAbs - preliminary data from the FINESSE study. MTIS 2022 Cephalalgia Abstracts. Cephalalgia. 2022;42(1_suppl):1-101. Go to original source...
    27. Ashina M, Mitsikostas DD, Amin FM. Kokturk P, Sahin G, Shankin CJ, Dorman PJ, Pozo-Rosich P, Lyras L, Myers C, Ahn A, Tassorelli C. Effectiveness of Fremanezumab for the Preventive Treatment of Migraine: Second Interim Analysis of the Observational PEARL Study. MTIS 2022 Cephalalgia Abstracts. Cephalalgia. 2022;42(1_suppl):1-101.
    28. Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol 2018;75(9):1080-1088. Go to original source... Go to PubMed...
    29. Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 2018;38:1442-1454. Go to original source... Go to PubMed...
    30. Camporeale A, Kudrow D, Sides R, Wang S, Van Dycke A, Selzler KJ, Stauffer VL. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurol 2018;18(1):188. Go to original source... Go to PubMed...
    31. Mulleners WM, Kim BK, Láinez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, Tockhorn-Heidenreich A, Aurora SK, Nichols RM, Yunes-Medina L, Detke HC. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19(10):814-825. Go to original source... Go to PubMed...
    32. Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine. The randomized, double-blind, placebo-controlled REGAIN study. Neurology 2018;91(24):e2211-e2221. Go to original source... Go to PubMed...
    33. Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia M, d'Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P; GARLIT Study Group. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain. 2021;22(1):35. Go to original source... Go to PubMed...
    34. Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Smith J. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241-254. Go to original source... Go to PubMed...
    35. Lipton RB, Saper J, Ashina M, Biondi D, Bhattacharya S, Hirman J, Schaeffler B, Cady R. A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab for the preventive treatment of chronic migraine: Results of the PROMISE-2 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-2) trial. Neurology 2018;90:E2193-E2194u.
    36. Kudrow D, Cady RK, Allan B, Pederson SM, Hirman J, Mehta LR, Schaeffler BA. Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurol. 2021;21(1):126. Go to original source... Go to PubMed...
    37. Ailani J, McAllister P, Winner PK, Chakhava G, Krog Josiassen M, Lindsten A, Sperling B, Ettrup A, Cady R. Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial. BMC Neurol. 2022;22(1):205. Go to original source... Go to PubMed...
    38. Nežádal T. Stanovisko Sekce pro diagnostiku a léčbu bolestí hlavy České neurologické společnosti ČLS JEP k personálnímu a technickému vybavení Center pro diagnostiku a léčbu bolestí hlavy a ke způsobu organizace jejich sítě se zaměřením na biologickou léčbu migrény. Cesk Slov Neurol N 2022;85(3):263-265.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.